twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2012
vol. 114
 
Share:
Share:
abstract:
Original paper

Frontalis suspension using autogenous fascia lata – evaluation of long-term outcome

Tomasz Dębski
1
,
Józef Jethon
1
,
Piotr Pietruski
1
,
Elżbieta Radzikowska
1

  1. Klinika Chirurgii Plastycznej Centrum Medycznego Kształcenia Podyplomowego w Warszawie
Online publish date: 2012/10/12
View full text Get citation
 
Purpose: To evaluate long-term outcome of frontalis suspension using autogenous fascia lata (frontalis suspension – FS) which

is indicated in the treatment of severe blepharoptosis with minimal levator function.

Material and methods: Fourty one patients (23 females, 18 males, aged 6–79 years, mean 41.4 years) who underwent FS

between 1999 and 2009 were evaluated. Mean follow-up was 55 months. Functional outcome was measured on digital photographs by analysis of an upper eyelid margin position below the superior limbus. Following criteria were used: very good

(< 3 mm), good (3–5 mm), unsatisfactory (>5 mm). Aesthetic outcome was assessed in terms of lid contour, symmetry of lid

height and lid crease. Patient satisfaction and life quality improvement were evaluated in the survey.

Results: Functional outcome was very good in 36%, good in 59.3%, unsatisfactory in 4.7%. Recurrence occured in 4,6% and

complications in 10,9% (lagophthalmos – 6.2%, entropion – 4.7%). Very good aesthetic outcome regarding lid contour, symmetry of lid height and lid crease was achieved in 76.6%, 53.6% and 51.6%, respectively.

Patient satisfaction and life quality improvement was also very high. There were only 1.6% unsatisfied patients.

Conclusions: FS is an efficient method in treatment of severe blepharoptosis.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.